BioLineRx’s (BLRX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of BioLineRx (NASDAQ:BLRX) in a research note published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $21.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for BioLineRx’s Q1 2024 earnings at ($0.29) EPS, Q2 2024 earnings at ($0.29) EPS, Q3 2024 earnings at ($0.24) EPS, Q4 2024 earnings at ($0.22) EPS, FY2024 earnings at ($1.03) EPS and FY2025 earnings at ($0.93) EPS.

Separately, StockNews.com upgraded BioLineRx to a sell rating in a research note on Monday, December 4th.

BioLineRx Trading Up 0.9 %

Shares of BLRX opened at $1.12 on Tuesday. The business has a 50-day moving average of $1.20 and a 200 day moving average of $1.46. BioLineRx has a fifty-two week low of $0.81 and a fifty-two week high of $2.53. The firm has a market cap of $81.13 million, a P/E ratio of -1.24 and a beta of 1.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.86 and a current ratio of 1.53.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings data on Tuesday, March 26th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.07. The firm had revenue of $4.80 million during the quarter, compared to analysts’ expectations of $0.17 million. During the same period last year, the business posted ($0.09) EPS. As a group, research analysts forecast that BioLineRx will post -0.91 EPS for the current year.

Institutional Trading of BioLineRx

A number of large investors have recently modified their holdings of BLRX. Renaissance Technologies LLC boosted its position in shares of BioLineRx by 377.6% during the 1st quarter. Renaissance Technologies LLC now owns 67,346 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 53,246 shares during the last quarter. Atria Wealth Solutions Inc. bought a new stake in shares of BioLineRx during the 1st quarter valued at about $178,000. LPL Financial LLC boosted its position in shares of BioLineRx by 152.7% during the 4th quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 71,134 shares during the last quarter. Envestnet Asset Management Inc. bought a new stake in shares of BioLineRx during the 1st quarter valued at about $88,000. Finally, Geneos Wealth Management Inc. lifted its position in BioLineRx by 72.3% in the 3rd quarter. Geneos Wealth Management Inc. now owns 40,500 shares of the biotechnology company’s stock worth $74,000 after buying an additional 17,000 shares during the last quarter. Institutional investors own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.